Lydia Usha

800 total citations
39 papers, 296 citations indexed

About

Lydia Usha is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, Lydia Usha has authored 39 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 13 papers in Genetics and 13 papers in Cancer Research. Recurrent topics in Lydia Usha's work include BRCA gene mutations in cancer (11 papers), PARP inhibition in cancer therapy (10 papers) and Cancer Genomics and Diagnostics (7 papers). Lydia Usha is often cited by papers focused on BRCA gene mutations in cancer (11 papers), PARP inhibition in cancer therapy (10 papers) and Cancer Genomics and Diagnostics (7 papers). Lydia Usha collaborates with scholars based in United States, United Kingdom and Singapore. Lydia Usha's co-authors include Ruta Rao, Melody Cobleigh, Lela Buckingham, Parul Barry, Akansha Chowdhary, Kirtesh R. Patel, Mudit Chowdhary, Dian Wang, Neilayan Sen and Andrew K. Godwin and has published in prestigious journals such as JAMA, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Lydia Usha

34 papers receiving 290 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lydia Usha United States 9 150 105 82 68 49 39 296
Betül T. Yesilyurt Belgium 8 194 1.3× 184 1.8× 140 1.7× 89 1.3× 38 0.8× 9 452
Sheau Wen Lok Australia 8 244 1.6× 179 1.7× 144 1.8× 82 1.2× 74 1.5× 25 431
Cristina Hernándo Spain 13 196 1.3× 188 1.8× 178 2.2× 114 1.7× 72 1.5× 46 414
Gabriele Rieck Germany 6 198 1.3× 206 2.0× 72 0.9× 46 0.7× 47 1.0× 8 370
Mohamad Kassar United States 6 138 0.9× 92 0.9× 53 0.6× 47 0.7× 17 0.3× 8 243
Liangqing Yao China 11 79 0.5× 124 1.2× 71 0.9× 41 0.6× 25 0.5× 38 442
Hal Hirte Canada 8 149 1.0× 155 1.5× 51 0.6× 45 0.7× 35 0.7× 11 333
Laura K. Nolden United States 6 132 0.9× 235 2.2× 47 0.6× 77 1.1× 18 0.4× 7 401
Kelly A. Shimabukuro United States 9 132 0.9× 171 1.6× 120 1.5× 94 1.4× 31 0.6× 17 353
Margit Stimpfl Austria 11 105 0.7× 193 1.8× 68 0.8× 32 0.5× 37 0.8× 16 372

Countries citing papers authored by Lydia Usha

Since Specialization
Citations

This map shows the geographic impact of Lydia Usha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lydia Usha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lydia Usha more than expected).

Fields of papers citing papers by Lydia Usha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lydia Usha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lydia Usha. The network helps show where Lydia Usha may publish in the future.

Co-authorship network of co-authors of Lydia Usha

This figure shows the co-authorship network connecting the top 25 collaborators of Lydia Usha. A scholar is included among the top collaborators of Lydia Usha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lydia Usha. Lydia Usha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Winkelman, L., et al.. (2024). A Prospective Trial of Serum Folate Levels in Women with Solid Tumor Malignancies Treated with Olaparib. Blood. 144(Supplement 1). 5224–5224.
2.
Chu, Jian, Changli Wei, Melody Cobleigh, et al.. (2024). Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study. Cardio-Oncology. 10(1). 3–3. 2 indexed citations
3.
Levy, Mia, et al.. (2022). Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors. Journal of the American College of Radiology. 20(1). 71–78. 2 indexed citations
4.
Usha, Lydia, et al.. (2021). Xenogeneic fibroblasts inhibit the growth of the breast and ovarian cancer cell lines in co-culture. Neoplasma. 68(6). 1265–1271. 3 indexed citations
5.
Cummings, Shelly, Jennifer Saam, Ryan Bernhisel, et al.. (2021). Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing. Journal of Ovarian Research. 14(1). 61–61. 11 indexed citations
6.
Chowdhary, Mudit, Neilayan Sen, Akansha Chowdhary, et al.. (2019). Safety and Efficacy of Palbociclib (CDK4/6 inhibitor) and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel Combination. International Journal of Radiation Oncology*Biology*Physics. 105(1). E2–E2. 2 indexed citations
7.
Chowdhary, Mudit, Neilayan Sen, Akansha Chowdhary, et al.. (2019). Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination. Advances in Radiation Oncology. 4(3). 453–457. 49 indexed citations
8.
Buckingham, Lela, et al.. (2018). Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation. Journal of the National Comprehensive Cancer Network. 16(5). 461–466. 19 indexed citations
9.
Buckingham, Lela, et al.. (2018). Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?. PLoS ONE. 13(4). e0195497–e0195497. 2 indexed citations
10.
Shammo, Jamile M., Lydia Usha, Parameswaran Venugopal, et al.. (2017). First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer. Blood. 130. 4748–4748.
11.
Cobleigh, Melody, et al.. (2017). Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. Breast Cancer Research and Treatment. 166(1). 315–319. 6 indexed citations
12.
Jakate, Shriram, et al.. (2017). Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy. Anticancer Research. 37(8). 4173–4176. 11 indexed citations
13.
14.
Williamson, Ashley J., Lydia Usha, Geetha Rao, et al.. (2014). Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress. Neoplasia. 16(10). 824–834. 28 indexed citations
15.
Katz, Deborah A., Ross A. Abrams, Joy S. Sclamberg, & Lydia Usha. (2014). Radiosensitizing effect of anti-HER2/neu agents: Report of 2 cases and review of the literature. Practical Radiation Oncology. 5(2). e61–e65. 5 indexed citations
16.
Usha, Lydia, Geetha Rao, Kent W. Christopherson, & Xiulong Xu. (2013). Mesenchymal Stem Cells Develop Tumor Tropism but Do Not Accelerate Breast Cancer Tumorigenesis in a Somatic Mouse Breast Cancer Model. PLoS ONE. 8(9). e67895–e67895. 13 indexed citations
17.
18.
Usha, Lydia, Larry E. Morrison, Ruta Rao, et al.. (2008). Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. Journal of Hematology & Oncology. 1(1). 12–12. 5 indexed citations
19.
Morrison, Larry E., Susan Jewell, Lydia Usha, et al.. (2007). Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes and Cancer. 46(4). 397–405. 19 indexed citations
20.
Usha, Lydia, Basil A. Bradlow, Wendy Stock, & Leonidas C. Platanias. (2000). CD5+ Immunophenotype in the Bone Marrow but Not in the Peripheral Blood in a Patient with Hairy Cell Leukemia. Acta Haematologica. 103(4). 210–213. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Betül T. Yesilyurt Breakdown of academic impact, for papers by Sheau Wen Lok Breakdown of academic impact, for papers by Cristina Hernándo Breakdown of academic impact, for papers by Gabriele Rieck Breakdown of academic impact, for papers by Mohamad Kassar Breakdown of academic impact, for papers by Liangqing Yao Breakdown of academic impact, for papers by Hal Hirte Breakdown of academic impact, for papers by Laura K. Nolden Breakdown of academic impact, for papers by Kelly A. Shimabukuro Breakdown of academic impact, for papers by Margit Stimpfl
Rankless by CCL
2026